<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248309</url>
  </required_header>
  <id_info>
    <org_study_id>2019-HRT-P-05</org_study_id>
    <nct_id>NCT04248309</nct_id>
  </id_info>
  <brief_title>Serum Progesterone Level in HRT-FET：a RCT</brief_title>
  <official_title>The Effect of Serum Progesterone Level on Day 3 in HRT-FET Cycles on the Clnical Outcome: a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the window of implantation, progesterone plays an important role. Sufficient serum
      progesterone is basic for ongoing pregnancy. Vaginal progesterone is more and more widely
      used in ART. As it has no hepatic first pass effect. What is the optimal serum level for
      pregnancy when use vaginal progesterone is not known yet? Hormone replacement therapy- FET is
      the optimal strategy to explore this question. There are some retrospective studies showed
      that the serum progesterone level on embryo transfer day (D3 or D5) or pregnancy test day
      (D14) lower than 10-11ng/ml is significantly associated with ongoing pregnancy rate in
      HRT-FET cycles. This prospective study is designed to compare the ongoing pregnancy rate
      between different serum progesterone levels on D3 and to explore the intervention of
      additional progesterone supplement since D3 is helpful in HRT-FET cycles.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>10 weeks after embryo transfer</time_frame>
    <description>beyond pregnancy week 12 in HRT-FET cycles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>10 weeks after embryo transfer</time_frame>
    <description>intrauterine gestational sacs by ultrasound</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">423</enrollment>
  <condition>Progesterone,Hormone Replacement Thawed Embryo Transfer Cycles</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone &lt;7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone &lt;7.24ug/L, followed by randomized A2：without additional treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group B：serum progesterone ≥7.24ug/L， without additional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intramuscular progesterone 20-40mg from D3 until pregnancy test</intervention_name>
    <description>serum progesterone &lt;7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）</description>
    <arm_group_label>A1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HRT-FET cycles，including GnRHa-HRT-FET

          2. Age&lt;41 years old

          3. BMI&lt;30kg/m2

          4. TSH and PRL normal

          5. Endometrium thickness ≥8mm on D0 6） embryo transfer completed with at least 1
             top-quality embryo (7-9 cell Grade 1 or D5 beyond grade 3 ) 7） Scandalized luteal
             phase support： transvaginal progesterone 0.2 tid with or without oral progesterone
             10mg bid 8） included once for every patient

        Exclusion Criteria:

          1. history of Moderate and Severe uterine adhesion；

          2. presence of hydrosapinx diameter &gt;2cm

          3. Endometrosis at stage III-IV

          4. Recurrent implantation failure (&gt;3 times of embryo transfer cycle)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Haiyan Lin</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

